Page last updated: 2024-12-11
bay v 3522
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6440069 |
MeSH ID | M0178233 |
Synonyms (11)
Synonym |
---|
bay v 3522 |
(6r,7r)-7-[[(2r)-2-amino-2-(2-amino-1,3-benzothiazol-6-yl)acetyl]amino]-8-oxo-3-[(z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
bay v-3522 |
7-(2-amino-2-(2-aminobenzothiazol-6-yl-acetoamide))-3-(1-propen-1-yl)-3-cephen-4-carboxylic acid |
75hlv3qoh7 , |
7-(2-amino-2-(2-aminobenzothiazol-6-yl-acetoamide))-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(2-amino-6-benzothiazolyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6r-(3(z),6alpha,7beta(r*)))- |
120635-27-0 |
unii-75hlv3qoh7 |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-amino(2-amino-6-benzothiazolyl)acetyl)amino)-8-oxo-3-(1z)-1-propenyl-, (6r,7r)- |
bay-v-3522 anhydrous |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |